Capricor Therapeutics Announces Initiation of Rolling Submission of Biologics License Application (Bla) With U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated